Evidence map›Paper›PMID 35020861›Full record

ArticleClinical and experimental immunology2021

Predictive biomarker modeling of pediatric atopic dermatitis severity based on longitudinal serum collection.

Sarah M Engle, Ching-Yun Chang, Benjamin J Ulrich, Allyson Satterwhite, Tristan Hayes, Kim Robling, Sean E Sissons, Jochen Schmitz, Robert S Tepper, Mark H Kaplan and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Clinical and experimental immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Clinical and Experimental Immunology: highlights from 2022.Clinical and experimental immunology · 2023
    Article
  5. Article
  6. Factors associated with severity of atopic dermatitis - a Finnish cross-sectional study.Journal of the European Academy of Dermatology and Venereology : JEADV · 2022
    Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Sarah M EngleEli Lilly and Company, Indianapolis, IN, USA.
Ching-Yun ChangEli Lilly and Company, Indianapolis, IN, USA.
Benjamin J UlrichDepartment of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN, USA.
Allyson SatterwhiteEli Lilly and Company, Indianapolis, IN, USA.
Tristan HayesDepartment of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN, USA.
Kim RoblingEli Lilly and Company, Indianapolis, IN, USA.
Sean E SissonsEli Lilly and Company, Indianapolis, IN, USA.
Jochen SchmitzEli Lilly and Company, Indianapolis, IN, USA.
Robert S TepperDepartment of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN, USA.
Mark H KaplanDepartment of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN, USA.
Jonathan T SimsEli Lilly and Company, Indianapolis, IN, USA.
Eli Lilly (United States) · USIndiana University School of MedicineIndiana University – Purdue University Indianapolis · US

Funding

Immunology and Infectious Diseases Training ProgramT32AI060519 · NIAID · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI MARK H KAPLAN · 2004 to 2026
$6.0M
Indiana Medical Scientist/Engineer Training ProgramT32GM077229 · NIGMS · INDIANA UNIVERSITY INDIANAPOLIS · PI GASTON, BENJAMIN, HERBERT, BRITTNEY-SHEA · 2008 to 2022
$6.0M
Cytokine regulation of skin barrier functionR01AI095282 · NIAID · INDIANA UNIVERSITY INDIANAPOLIS · PI KAPLAN, MARK H · 2012 to 2022
$4.3M
IL-9-secreting tissue-resident memory T cells in allergic airway diseaseF30HL147515 · NHLBI · INDIANA UNIVERSITY INDIANAPOLIS · PI ULRICH, BENJAMIN · 2019 to 2019
$30k
NHLBI NIH HHS F30 HL147515NIAID NIH HHS R01 AI095282NIAID NIH HHS T32 AI060519NIGMS NIH HHS T32 GM077229
6 · The paper itself

Abstract

The pathogenesis of atopic dermatitis (AD) results from complex interactions between environmental factors, barrier defects, and immune dysregulation resulting in systemic inflammation. Therefore, we sought to characterize circulating inflammatory profiles in pediatric AD patients and identify potential signaling nodes which drive disease heterogeneity and progression. We analyzed a sample set of 87 infants that were at high risk for atopic disease based on atopic dermatitis diagnoses. Clinical parameters, serum, and peripheral blood mononuclear cells (PBMCs) were collected upon entry, and at one and four years later. Within patient serum, 126 unique analytes were measured using a combination of multiplex platforms and ultrasensitive immunoassays. We assessed the correlation of inflammatory analytes with AD severity (SCORAD). Key biomarkers, such as IL-13 (rmcorr=0.47) and TARC/CCL17 (rmcorr=0.37), among other inflammatory signals, significantly correlated with SCORAD across all timepoints in the study. Flow cytometry and pathway analysis of these analytes implies that CD4 T cell involvement in type 2 immune responses were enhanced at the earliest time point (year 1) relative to the end of study collection (year 5). Importantly, forward selection modeling identified 18 analytes in infant serum at study entry which could be used to predict change in SCORAD four years later. We have identified a pediatric AD biomarker signature linked to disease severity which will have predictive value in determining AD persistence in youth and provide utility in defining core systemic inflammatory signals linked to pathogenesis of atopic disease.

Indexed as

Atopic DermatitisIL-13pediatricSCORADTARC/CCL17

Identifiers

PMID35020861
PMCPMC9113166
OpenAlexW4225343779

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.